ArticleStem cell research2025
Generation of induced pluripotent stem cell lines from patients with thoracic aortic aneurysm carrying the ACTA2 gene mutation.
Article in Stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Generation of two iPSC lines from ALS patients harboring C9orf72 hexanucleotide repeat expansions.Stem cell research · 2026Article
- Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients with TTN mutations.Stem cell research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thoracic aortic aneurysms (TAA) are abnormal dilations of the aorta above the diaphragm. Mutations in the ACTA2 gene are among the most common genetic causes of TAA. Induced pluripotent stem cells (iPSCs) provide a platform for comprehensive biological investigations and the development of tailored medical strategies for this condition. Here, two iPSC lines were generated from TAA patients harboring the ACTA2 mutation, c.773 G > A. Both iPSC lines demonstrated characteristic pluripotent stem cell morphology, expressed core pluripotency markers, maintained normal karyotypes, and possessed the capacity for trilineage differentiation. These cell lines represent a valuable resource for studying the genetic and cellular mechanisms underlying TAA pathogenesis associated with ACTA2 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.